LDHA and GO dual inhibitor

in vitro activity and X-ray vs. both targets

from SBDD of LDHA and GO inhibitors

ACS Med. Chem. Lett., May 20, 2021

Chinook Therapeutics, Seattle, WA

The Chinook LDHA/GO dual inhibitor, compound 7, targets two clinically validated targets for hyperoxaluria, a rare genetic disorder that results in oxalate overproduction and sometimes kidney failure. GO is encoded…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.